media – Page 70 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

ETH Zurich researchers reveal how colorectal cancer cells colonise the liver

Researchers from ETH Zurich, Switzerland, have revealed how colorectal cancer cells colonise the liver, which could help to develop future treatments that can be a hindrance to the formation of often fatal metastases. The study published in Nature Cell was led by Andreas Moor, an assistant professor in the department of biosystems science and engineering at ETH Zurich. Currently the third most common cancer type worldwide and the second most common cause of cancer death, colorectal cancer, otherwise known as bowel cancer, occurs when abnormal cells start to divide and grow in an uncontrolled way in the large bowel and back passage. In most cases of fatal cancer, metastasis is the most likely cause, which occurs when the primary tumour has sent out cells and invaded other organs of the body. With no current treatment to prevent the metastatic process, researchers tested on genetically modified mice and discovered that a ...
- Source: drugdu
- 78
- August 7, 2024
New study reveals certain bacteria are toxic for head and neck cancer

Researchers from Guy’s and St Thomas’ and King’s College London (KCL) have revealed a certain type of bacteria is toxic for head and neck cancer and could potentially lead to better outcomes for patients. Published in Cancer Communications, the research was funded by Guy’s Cancer Charity and Cancer Research UK through the City of London Cancer Centre. Currently the sixth most common cancer globally, head and neck cancers affect around 1,000 people in the UK every month. When analysing head and neck cancer patients, the team found that those who harboured higher levels of Fusobacterium, which is usually associated with the progression of bowel cancer, had a better prognosis than those with lower levels of the bacteria. In total, there was a 70% to 99% reduction in the number of viable cancer cells in head and neck cancer cell cultures after being infected with the bacterium, as it destroys the ...
- Source: drugdu
- 82
- August 7, 2024
KOREA PHARM & BIO

Organiser：KOREA PHARM & BIO Time：April 22nd – 25th, 2025 address：217-59 Kintekseu-ro, Daehwa-dong, Ilsanseo-gu, Goyang-si, Gyeonggi-do, Korea Exhibition hall：KINTEX Product range: Pharmaceuticals: Pharmaceutical Raw Materials, Active Pharmaceutical Ingredients (APIs), Pharmaceutical Fine Chemicals, Intermediates, Pharmaceutical Additives, Pharmaceutical Dosage Forms, Natural Extracts, Biotechnology, Pharmaceutical Outsourcing and Services, Laboratory Equipment, Pharmaceutical Manufacturing Equipment, etc. Chemicals: Chemical Raw Materials, Chemical Equipment, Instrumentation, Automation Control Technology, Heat Exchangers, Crystallization, Gas Absorption, Drying, Filtration, Centrifugal Separators, Dust Collection, Chemical Reactors, Crushers, Mixers, etc. Cosmetics: Cosmetic Raw Materials, Cosmetic Additives, Functional Materials, Natural Extracts, etc. About KOREA PHARM & BIO： KOREA PHARM & BIO is one of the most influential pharmaceutical and biotechnology exhibitions in Korea and Asia. It is jointly organized by the Korea Food and Drug Administration (KFDA), Korea Pharmaceutical Manufacturers Association (KPMA), and Kyungyon Exhibition Company in Korea.
- Source: drugdu
- 129
- August 7, 2024
【EXPERT Q&A】What do regulatory and non-regulatory markets mean?

Drugdu.com expert’s response: Drug regulatory market and non-regulatory market are two relative concepts, and they have significant differences in the regulation, production and sale of drugs. Ⅰ. Pharmaceutical Regulatory Market The pharmaceutical regulatory market can be understood as one that adheres to the standards and guidelines set forth by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). These markets typically operate under stringent legal and regulatory frameworks, imposing rigorous oversight on drug research and development, production, and sales. Specifically, the pharmaceutical regulatory market necessitates that drugs comply with relevant quality and safety standards and undergo rigorous approval processes before being marketed and sold. In such markets, government regulatory authorities rigorously supervise and manage drugs to ensure their quality and safety. Ⅱ. Unregulated Market The unregulated market, on the other hand, refers to markets that operate in violation of local laws and regulations. These markets ...
- Source: drugdu
- 99
- August 7, 2024
FDA Grants Accelerated Approval to Adaptimmune Therapeutics’ Tecelra for Adults with Synovial Sarcoma Who Have Undergone Prior Chemotherapy

By Don Tracy, Associate Editor Regulatory action marks the first engineered cell therapy approved for a solid tumor cancer in the United States.The FDA has granted accelerated approval to Adaptimmune Therapeutics’ Tecelra (afamitresgene autoleucel), an engineered cell therapy that targets resectable or metastatic synovial sarcoma in adults who have undergone prior chemotherapy and are HLA-A*02 positive with MAGE-A4 antigen expression. The treatment, which was approved based on results from the SPEARHEAD-1 trial, marks the first engineered cell therapy for a solid tumor cancer to be approved in the United States, according to the company.1 “The approval of Tecelra is a momentous step in Adaptimmune’s journey to redefine the way cancer is treated and the culmination of a decade of groundbreaking R&D. I want to thank the patients, caregivers, investigators, and clinical teams as well as everyone at Adaptimmune and our partners who made possible this watershed moment for cell therapy ...
- Source: drugdu
- 97
- August 6, 2024
Jade Bio’s Launch, Brenig’s Debut, Confo’s Cash & More

Recent financing news includes several companies raising money to advance their research to the clinic. Here’s a look back at funding rounds from companies such as Outpace Bio, GRO Biosciences, and Confo Therapeutics. By Frank VinluanOne challenge for developing drugs for autoimmune diseases is that biologic therapies can spark an immune response against them. Immunology and inflammation research is coming up with new approaches to reduce the risk of such responses. That science is progressing in the hands of new companies raising fresh rounds of capital. Inflammation and immunology figures prominently in recent funding news, which includes several companies approaching the clinic with novel biologic drugs. Here’s a recap of recent biotech financings, grouped according to therapeutic area: Immunology & Inflammation —Abiologics unveiled an artificial intelligence-driven platform technology for designing novel biologic drugs based on non-standard amino acids. The startup, which has been incubating within Flagship Pioneering for the past ...
- Source: drugdu
- 92
- August 6, 2024
Porton Advanced and Geneseed Biotech Enter into Strategic Collaboration to Focus on Advancing circRNA Innovative Therapeutics

SUZHOU, China, July 30, 2024 /PRNewswire/ — On July 29, 2024, Porton Advanced Solutions (“Porton Advanced”) announced that it had reached a strategic cooperation with Guangzhou Geneseed Biotech Co., Ltd (“Geneseed Biotech”). Both sides will combine their respective strengths in the field of gene therapy to jointly provide better drug development services. Leveraging Porton Advanced’s end-to-end cell and gene therapy CDMO service platform and resource advantages, combined with Geneseed Biotech’s comprehensive core patented technologies in circRNA drug concept validation and process development, the two companies will jointly propel technological innovation and clinical translation, thereby accelerating the implementation of innovative circRNA therapies. Proton Advanced is committed to providing end-to-end CDMO services for cell and gene therapy, and has extensive experience in nucleic acid therapy process development and GMP production, covering various types including mRNA, saRNA, circRNA, and more. Porton Advanced can provide comprehensive CMC services from preclinical to clinical production. Geneseed ...
- Source: drugdu
- 117
- August 6, 2024
WuXi Biologics’ Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics

WUXI and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that four manufacturing facilities and Suzhou Biosafety Testing Center in China have received Good Manufacturing Practice (GMP) certificates from the European Medicines Agency (EMA), demonstrating the company’s commitment to meeting rigorous international industry quality standards across its global network. Following comprehensive inspections of the company’s facilities– specifically MFG1, MFG2, MFG5, and DP1 in Wuxi– EMA GMP certificates were issued for commercial and New Drug Application (NDA)-ready manufacturing and services for eight biologics, an endorsement to the company’s capabilities in providing such services for global clients. All of these facilities were previously approved by the EMA and other major regulatory authorities for the development of multiple biologic therapeutics. Furthermore, the company’s Suzhou Biosafety Testing Center was once again certified by the EMA to provide services ...
- Source: drugdu
- 79
- August 6, 2024
Study reveals non-statin cholesterol drugs could reduce liver cancer risk

by Jen Brogan A study conducted by researchers from the National Cancer Institute (NIH) has revealed that non-statin cholesterol drugs could reduce the risk of liver cancer. Published in the American Cancer Society’s CANCER, researchers looked for associations between five types of non-stain cholesterol-lowering medications and the risk of liver cancer. Accounting for more than 700,000 deaths each year, liver cancer is the sixth most commonly occurring cancer globally and the third leading cause of cancer mortality. Non-statin cholesterol-lowering medications such as cholesterol absorption inhibitors, bile acid sequestrants, fibrates, niacin and omega-3 fatty acids all work in different ways and are prescribed to manage cholesterol and lipid levels. Using information from the Clinical Practice Research Datalink, which covers around 7% of the UK population, researchers analysed 3,719 liver cancer cases and 14,876 matched controls without cancer. Additional matches were also made based on patients’ type 2 diabetes and chronic liver ...
- Source: drugdu
- 81
- August 6, 2024
Researchers reveal CAR-enhancer therapy could help overcome cancer relapse

Cancer is estimated to affect more than three million people living in the UK, according to Macmillan Cancer Support Researchers from the Dana-Farber Cancer Institute have revealed in a study that CAR-enhancer (CAR-E) therapy could help patients overcome cancer relapse. In the findings published in Nature Biotechnology, researchers report on a technique to prevent relapse and researchers hope to launch the first trial in the near future. It is estimated that there are more than three million people living in the UK with cancer, according to Macmillan Cancer Support, with breast cancer being the most prevalent, accounting for more than 55,000 new cases every year. A common challenge faced when using CAR T-cell therapies is that many patients, including those whose cancer has gone into full remission, eventually relapse. To eliminate this problem, the new techniques create what researchers consider a CAR-E therapeutic platform, which causes CAR T cells to ...
- Source: drugdu
- 113
- August 6, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.